Limitations and Remaining Questions While semaglutide has shown significant benefits in reducing joint pain among patients with obesity, several important limitations remain: Studies often lack post-treatment follow-up, making it unclear how durable these pain and weight outcomes are once medication is stopped
International Journal of Molecular Sciences , 24 , 7150 Zhang, Q
What matters is the interval between doses
But the big question is how well its growth will hold up in the future, as other GLP-1 drugs inevitably enter the market
However, you are more likely to experience severe side effects such as nausea, vomiting, hypoglycemia or low blood sugar levels, and diarrhea with high dosage